Rose Ann Blenman Abange, Ph.D, Cpm
Director, Lci Biomarker Strategy And Portfolio Management @ Johnson & Johnson
About Rose Ann Blenman Abange, Ph.D, Cpm
Rose Ann Blenman Abange, Ph.D., Cpm, serves as the Director of LCI Biomarker Strategy and Portfolio Management at Johnson & Johnson. With a background in biomedical engineering and extensive experience in oncology biomarkers, she has held significant roles at Merck and RoseCeutics LLC and is an advocate for STEM education in BIPOC communities.